Bradykinin-induced angioedema and its differential diagnosis

Česká verzia

Authors: P. Králíčková ¹; E. Malá ¹; P. Rozsíval ²; Jana Krtičková ³ ; I. Krčmová ¹
Authors place of work: Univerzita Karlova v Praze, Lékařská fakulta a Fakultní nemocnice Hradec Králové ; Ústav klinické imunologie a alergologie, Přednosta: prof. RNDr. Jan Krejsek, CSc. ¹; Dětská klinika, Přednosta: prof. MUDr. Milan Bayer, CSc. ²; Klinika otorinolaryngologie a chirurgie hlavy a krku, Přednosta: prof. MUDr. Viktor Chrobok, Ph. D. ³
Published in the journal: Prakt. Lék. 2012; 92(7): 378-382
Category: Reviews

Summary

A significant proportion of population has experience with angioedema. According to the pathophysiology it is possible to subdivide angioedema into histamine- or bradykinin induced. They fundamentally differ from each other in aetiology, clinical picture and management. This article is focused on bradykinin-induced angioedema, comprising: hereditary angioedema, ACE-inhibitors induced-angioedema and acquired angioedema. These diagnoses are often neglected. Inadequate treatment could lead to a patient’s death. C1 inhibitor substitution and bradykinin-receptor blocker play key roles in the management of the condition. Corticosteroids, antihistamines or adrenalin are ineffective in such cases.

Key words:
angioedema, bradykinin, hereditary, C1 inhibitor, icatibant

Zdroje

1. Adam, A., Cugno, M., Molinaro, G., et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002, 359(9323), p. 2088–2089.

2. Antoniu, S.A. Therapeutic approaches in hereditary angioedema. Clinic Rev Allerg Immunol 2011, 41(1), p. 114–122.

3. Bas, M., Grepe, J., Shelter, K., et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010, 56(3), p. 278–282.

4. Bork, K. Hereditary angioedema: New findings concerning symptome, affected organs, and course. Am J Med 2006, 119(3), p. 267–274.

5. Bowen, T. Management of hereditary angioedema: a Canadian approach. Transfus Apher Sci 2003, 29(3), p. 205–214.

6. Caldwell, J.R., Ruddy, S., Schur, P.H. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol 1972, 1, p. 39–42.

7. Caballero, T., Baeza, M.L., Cabañas, R., et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathyphysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 2011, 21(5), p. 333–347.

8. Caballero, T., Baeza, M.L., Cabañas, R., et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol 2011, 21(6), p. 422-441.

9. Caballero T. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Clin Immunol 2012, 129(2), p. 308–320.

10. Cicardi, M. How do we treat patients with hereditary angioedema. Transfus Apher Sci 2003, 29(3), p. 221–227.

11. Cicardi, M., Zanichelli, A. Acquired angioedema. Allergy Asthma Clin Immunol 2010, 6(1), p. 14.

12. Cicardi, M. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010, 363(6), p. 532–541.

13. Cichon, S. Increased activity of coagulation factor XII (Hageman factor) cause hereditary angioedema type III. Am J Hum Gen 2006, 79(6), p. 1098–1104.

14. Cugno, M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trend Mol Med 2009, 15(2), p. 69–78.

15. Craig, T. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Astma Immunol 2009, 102(5), p. 366–372.

16. Craig, T.J. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin. Immunol 2009, 124(4), p. 801-808.

17. Davis, B., Bernstein, J.A. Conestat alfa for the treatment of angioedema attacks. Ther Clin Risk Manag 2011, 7, p. 265–273.

18. DeSerres, J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinet P) in hereditary angioedema: a review. Transf Apher Sci 2003, 29(3), p. 247–254.

19. Duerr, M., Glander, P., Diekmann F., et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010, 5(4), p. 703–708.

20. Fincham, C.I. Bradykinin receptor antagonist - a review of the patent literature 2005-2008. Expert Opin Ther Pat 2009, 19(7), p. 919–941.

21. Frank, M.M., Juany, H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol 2008, 121(1), p. 272–280.

22. Frank, M.M., Sergent, J.S., Kane, M.A., et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972, 286(15), p. 808–812.

23. Gompels, M. M., Lock R.J., Abinun M., et al. C1 inhibitor deficiency: consensus document. Clin Exp Imunol 2005, 139(3), p. 379–394.

24. Haymore, B.R., Yoon, J., Mikita, C.P., et al. Risk of angioedema with angiotensin receptor blockers on patients with prior angioedema associated angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 2008, 101(5), p. 495–499.

25. Hoover, T., Lippmann, M., Grouzmann, E., et al. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy 2010, 40(1), p. 50–61.

26. Christiansen, S.C. Update on therapeutic developments for hereditary angioedema. Allergy Astma Proc 2009, 30(5), p. 500–505.

27. Krejsek, J. Kopecký, O. Klinická imunologie. Hradec Králové: Nucleus, 2004, s. 181–196.

28. Kuklínek, P. Hereditární a získaný angioedém (deficit C1-INH). In: Špičák, V. a kol. Alergologie. Praha: Galén, 2004, s. 257–262.

29. Longhurst, H., Cicardi, M. Hereditary angio-oedema. Lancet 2012, 379(9814), p. 474–481.

30. Malde, B., Regalado, J., Greenberger, P.A. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007, 98(1), p. 57–63.

31. Nussberger, J., Cugno, M., Cicardi, M., et al. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999, 104(6), p. 1321–1322.

32. Petrů V., Krčmová I. Anafylaktické reakace. Praha: Jessenius Maxdorf, 2006, s. 18-53, 60–67.

33. Picone, O., Donnadieu, A.C., Briket, F.G., et al. Obstetrical complications and outcome in two families with hereditary angioedema due to mutationn in the F12 gene. Obstet Gynecol Int 2010; 957507. Published online 2010 May 13. doi: 10.1155/2010/957507.

34. Quan, M. Case study. ACE inhibitor-induced angioedema. Clin Cornerstone 2009, 9(3), p. 34–35.

35. Rosen, F.S. Deficiencies of C1 inhibitor. Best Pract Res Clin Gastroenterol 2005, 19(2), p. 251–261.

36. Scheirey, C.D., Schulz, F.J., Shortsleeve, M.J., et al. Angiotensin-converting enzyme inhibitor-induce small-bowel angioedema: clinical and imaging findings in 20 patients. Am J Roentgenol 2011, 197(2), p. 393–398.

37. Špičák, V., Panzner, P. Alergologie. Praha: Galén, 2004, s. 246-252, 272–176.

38. Zingale, L.C, Castelli, R., Zanicheli,, A., Cicardi, M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and convential management. Immunol Allergy Clin North Am 2006, 26(4), p. 669–690.